MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH ("Ketabon" or
"the Company"), a joint venture between HMNC Brain Health (https://www.hmnc-
brainhealth.com/) and Develco Pharma
(https://www.develco.ch/?page_id=3300&lang=en), announced today the Company will
present poster presentations at the American Society of Clinical
Psychopharmacology (ASCP) Annual Meeting (https://ascpp.org/ascp-meetings/ascp-
annual-meeting/) taking place on May 28-31, 2024 at Miami Beach.
Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC Brain Health, will
elucidate details on topline results
(https://www.ketabon.health/news/Ketabon_GmbH_Reports_Top-
Line_Results_from_Phase_2_Trial_of_Take-at-Home) of its Phase 2 trial with
KET01, an oral ketamine treatment with minimal side effects, showing rapid
improvements in depression severity and Ketabon's comparative study
(https://www.ketabon.health/news/Head-to-head-Trial-of-Prolonged-Release-Oral-
Ketamine-Formulation) between KET01 and intranasal SPRAVATO®, the current FDA-
approved ketamine formulation.
Presentation details are as follows:
Session: W16
Poster: Comparison of Tolerability, Safety, and Pharmacokinetics of
Antidepressant Doses of Oral Ketamine Prolonged Release Tablets (KET01) and
Intranasal Esketamine: A Randomized, Placebo-Controlled, Double-Blind, Cross-
Over Trial
(https://www.globenewswire.com/Tracker?data=UpOmZplx3DSoPmUWWUlooMufvfSS1TBZdC1S
sxGPdEZsO3eLOX7Op-gZ-qCp-
AbeuIU_kx4YR6ajCrFXtTrgByygyoZH9FNVgq7B3LQjEIuUDEfov4cpqWcVX2ccfGd-
tkh07_M3hrRBvOx_xBxwdH07SwP9ga7zmCYovUTTylEkpn7bIM2tE7xD98W-XBH-
3Ut6V6l_tSsvpeqxS5h62nPROMG2wiYbzQLaCMT-3L_rT_cXAI8PfMW1W_Al70Y2)Presenter: Hans
Eriksson, M.D., Ph.D., CMO at Ketabon
Date & Time: Wednesday, May 29, 2024 from 11:15 am to 1 pm ET
Session: T17
Poster: A Randomized Placebo-Controlled Double-Blind Phase 2 Trial of Adjunctive
KET01 (Oral Prolonged-Release Ketamine) for Treatment-Resistant Depression
(https://www.globenewswire.com/Tracker?data=UpOmZplx3DSoPmUWWUlooMufvfSS1TBZdC1S
sxGPdEZsO3eLOX7Op-gZ-qCp-
AbeuIU_kx4YR6ajCrFXtTrgByygyoZH9FNVgq7B3LQjEIuUDEfov4cpqWcVX2ccfGd-
tkh07_M3hrRBvOx_xBxwdH07SwP9ga7zmCYovUTTylEkpn7bIM2tE7xD98W-XBH-
3Ut6V6l_tSsvpeqxS5h62nPROMG2wiYbzQLaCMT-3L_rT_cXAI8PfMW1W_Al70Y2)Presenter: Hans
Eriksson, M.D., Ph.D., CMO at Ketabon
Date & Time: Thursday, May 30, 2024 from 12:30 pm to 2:15 pm ET
Pharmaceutical Pipeline Session
Topic: Oral Prolonged-Release Adjunctive Ketamine (KET01): Phase 2 Trial in
Treatment-Resistant Depression and Phase 1 Trial Comparing Tolerability with
Intranasal Esketamine
(https://www.globenewswire.com/Tracker?data=UpOmZplx3DSoPmUWWUlooMufvfSS1TBZdC1S
sxGPdEZsO3eLOX7Op-gZ-qCp-
AbeuIU_kx4YR6ajCrFXtTrgByygyoZH9FNVgq7B3LQjEIuUDEfov4cpqWcVX2ccfGd-
tkh07_M3hrRBvOx_xBxwdH07SwP9ga7zmCYovUTTylEkpn7bIM2tE7xD98W-XBH-
3Ut6V6l_tSsvpeqxS5h62nPROMG2wiYbzQLaCMT-3L_rT_cXAI8PfMW1W_Al70Y2)Presenter: Hans
Eriksson, M.D., Ph.D., CMO at Ketabon
Date & Time: Thursday, May 30, 2024 at 3:00 pm ET
"We are honored to speak at the premier CNS drug development gathering, where
we'll be sharing KET01's potential to significantly simplify treatment and
provide an option for care beyond clinical settings, ensuring comfort and
convenience for patients at home," said Dr. Hans Eriksson, Chief Medical Officer
of Ketabon and HMNC Brain Health. "As a company committed to pioneering
personalized therapies in psychiatry, we're deeply grateful for the opportunity
to continue advancing alternative treatments for patients grappling with
treatment-resistant depression."
For more information on the Ketabon program, please visit
https://www.ketabon.health/.
About the Ketabon Program
The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma comprises an oral prolonged-release formulation of ketamine for TRD (KET01) with minimal dissociative side effects, that could make it the first ketamine treatment for depression suitable for use at home. The pharmacokinetic profile of the prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects compared to the currently applied intravenous and intranasal ketamine therapies resulting in a decreased need for monitoring under medical supervision. TRD patients with insufficient response to standard antidepressants represent close to 30% of an overall estimated number of 320 million patients worldwide suffering from major depressive disorder. Clinical development of oral prolonged-release ketamine could also be potentially expanded into other indications beyond depression, such as anxiety, aggression, PTSD, and panic disorder.
About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma
company headquartered in Munich, Germany which is pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to higher remission rates. The company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The company has presence in both Germany and the U.S. and is backed by a renowned global VC, several family offices, and a strategic healthcare investor.
More information at www.hmnc-brainhealth.com (http://www.hmnc-brainhealth.com)
About Develco Pharma
Develco Pharma is a Swiss-German pharmaceutical company headquartered in Pratteln, Switzerland, specializing in the development and manufacture of orally
administered modified, prolonged & chrono-release drugs containing known active ingredients. Established in 2006, today the company has a workforce of 130
employees. A state-of-the-art production facility for analgesics and drugs for the treatment of other indications has been in operation in Schopfheim, in Germany, since 2016. Develco identifies and defines pharmaceutical products containing known active ingredients and develops generic, hybrid, value-added, and innovative formulations backed by clinical data for the delayed or modified release of active ingredients. On the strength of its experience and innovativeness, the company has emerged as an internationally recognized provider of pharmaceuticals for the treatment of several disease areas. The customer base of Develco Pharma includes global pharmaceutical groups. The company has some 180 market approvals in all (products of different dosages) in Europe, the US, Middle East, South Africa, Asia, and Australia. More information
at www.develco.ch (http://www.develco.ch)
Media contacts (U.S.):
Anne Donohoe
+1212.896.1265
hmncbrain@kcsa.com
Â